GLP-1 Agonists Companies

The global GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period. Factors such as API and fill finish manufacturing expansions are enhancing supply capacity to meet surging global demand for these therapies. Indication expansion, such as approvals for additional metabolic and cardiovascular conditions, is broadening patient access and driving adoption. Moreover, the rising prevalence of obesity and type 2 diabetes (T2D) globally continues to significantly boost market demand, as GLP-1 agonists play a pivotal role in the treatment and management of these conditions.

The global GLP-1 agonists market is consolidated with leading players contributing to a significant share, including Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), among others. The market players have undertaken developments such as acquisitions, agreements, collaborations, and geographical expansions to strengthen their position in the global GLP-1 agonists market.

To know about the assumptions considered for the study download the pdf brochure

In August 2025, BioMed X (US) and Novo Nordisk (Denmark) collaborated to drive innovation in oral formulations for peptide drugs such as GLP-1 receptor agonists. In September 2025, Pfizer (US) announced plans to acquire Metsera, entering into a definitive agreement. This acquisition aims to enhance its portfolio with the addition of Metsera's Next-Generation Obesity Portfolio.

Novo Nordisk (Denmark)

Novo Nordisk is a global leader in metabolic disease innovation, renowned for pioneering GLP-1 agonists such as semaglutide (Ozempic, Wegovy, Rybelsus) that transform diabetes and obesity care. The company’s strategic roadmap is marked by continued investment in R&D, with a robust late-stage pipeline and recent launches addressing new indications like cardiovascular risk reduction, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH). The company has embarked on major manufacturing expansions to meet surging demand, acquiring new production sites to secure global supply chain resilience. The company harnesses advanced technologies such as AI-driven drug discovery, innovative formulations, and digital health solutions. Novo Nordisk focuses on enhancing scale, innovation, and therapeutic breadth, thus retaining its strategic position in the rapidly growing GLP-1 agonists market.

Eli Lilly (US)

Eli Lilly is another leading player in the GLP-1 agonists market, leveraging its dual agonist, tirzepatide (Mounjaro, Zepbound), which has significantly driven growth in obesity and diabetes therapeutics through 2025. The company is innovating with next-generation oral GLP-1 receptor agonists, such as orforglipron, offering enhanced patient accessibility and adherence by eliminating injection barriers. Eli Lilly is also scaling manufacturing capacity in response to surging demand to ensure robust production and global reach. Strategic pipeline diversification, including metabolic and cardiology solutions, as well as competitive pricing and proactive label expansion, uniquely position Eli Lilly to address market needs and maintain long-term leadership in the GLP-1 sector. These combined efforts, spanning R&D, manufacturing, and commercial innovation, have enabled Lilly to drive advances in obesity and diabetes management on a global scale.

Sanofi (US)

Sanofi is another key player in the market with a commercialized GLP-1 combination drug. Soliqua is an innovative fixed-ratio combination of insulin glargine and the GLP-1 receptor agonist lixisenatide, specifically targeting adults with type 2 diabetes. Unlike competitors focused mainly on North America and Europe, Sanofi excels in global reach, securing approval for Soliqua in over 80 countries and actively expanding access in emerging markets, such as recent launches in India (2024). Soliqua is recognized for simplifying diabetes management by offering sustained glycemic control and minimizing weight gain through a convenient once-daily injection, thus addressing patient burdens associated with multiple therapies. The company focuses on combination therapies and robust supply chain infrastructure, giving it an edge in global distribution and accessibility, even as it pivots R&D efforts toward immunology and other complex disease areas. This positions Sanofi as a key player in diabetes care, delivering innovative GLP-1 solutions on a global scale.

Market Ranking

The GLP-1 agonists market is highly consolidated. The top three players hold >95% share of the market.

In the GLP-1 agonists market, Novo Nordisk maintains a strong position through a comprehensive portfolio of products and wide therapeutic area coverage. The company maintains its strategic position by expanding geographic reach. Eli Lilly is enhancing its presence significantly in the GLP-1 agonists market with the growing demand for its key product, Mounjaro. Sanofi, although not a significant contributor, is sustaining in the rapidly expanding GLP-1 market space.  The market is expected to witness several new players entering with the launch of semaglutide biosimilars and combination products.

Related Reports:

GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com